On the basis of the data suggesting that adolescents and young adult patients with acute lymphoblastic leukemia (ALL) have improved outcomes when treated on pediatric protocols, we assessed the ...

The rare hematologic malignancy known as chronic myelomonocytic leukemia was the subject of a recent study that compared outcomes from patients treated at academic centers versus nonacademic centers.

While it is the most common form of leukemia in adults, it's still considered rare as there are fewer than 200,000 cases in ...

Tisagenlecleucel (tisa-cel) is approved for patients ≤25 years, while brexucabtagene autoleucel (brexu-cel) is licensed for adults ≥18 years. obe-cel utilizes a novel intermediate-affinity ...

One such type is Acute Lymphoblastic Leukemia (ALL), which is characterised ... The condition is most prevalent in children but can also occur in adults, affecting their overall health and quality ...

Aucatzyl Approved for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Danziten (nilotinib) Kinase inhibitor For the treatment of adults with newly diagnosed Philadelphia chromosome ...

for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Approval was based on results from the ...

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Refractory Acute Myeloid Leukemia.